614 related articles for article (PubMed ID: 25656912)
1. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.
Pain C; Dumont J; Dumoulin M
Biochimie; 2015 Apr; 111():82-106. PubMed ID: 25656912
[TBL] [Abstract][Full Text] [Related]
2. Introduction to heavy chain antibodies and derived Nanobodies.
Vincke C; Muyldermans S
Methods Mol Biol; 2012; 911():15-26. PubMed ID: 22886243
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases.
Limbocker R; Cremades N; Cascella R; Tessier PM; Vendruscolo M; Chiti F
Acc Chem Res; 2023 Jun; 56(12):1395-1405. PubMed ID: 37071750
[TBL] [Abstract][Full Text] [Related]
4. A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formation.
De Genst E; Chan PH; Pardon E; Hsu SD; Kumita JR; Christodoulou J; Menzer L; Chirgadze DY; Robinson CV; Muyldermans S; Matagne A; Wyns L; Dobson CM; Dumoulin M
J Phys Chem B; 2013 Oct; 117(42):13245-13258. PubMed ID: 23919586
[TBL] [Abstract][Full Text] [Related]
5. Nanobodies as structural probes of protein misfolding and fibril formation.
De Genst E; Dobson CM
Methods Mol Biol; 2012; 911():533-58. PubMed ID: 22886275
[TBL] [Abstract][Full Text] [Related]
6. Novel therapy based on camelid nanobodies.
Unciti-Broceta JD; Del Castillo T; Soriano M; Magez S; Garcia-Salcedo JA
Ther Deliv; 2013 Oct; 4(10):1321-36. PubMed ID: 24116915
[TBL] [Abstract][Full Text] [Related]
7. Camelid nanobodies: killing two birds with one stone.
Desmyter A; Spinelli S; Roussel A; Cambillau C
Curr Opin Struct Biol; 2015 Jun; 32():1-8. PubMed ID: 25614146
[TBL] [Abstract][Full Text] [Related]
8. Preparation of a naïve library of camelid single domain antibodies.
Olichon A; de Marco A
Methods Mol Biol; 2012; 911():65-78. PubMed ID: 22886246
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases.
Cheng B; Gong H; Xiao H; Petersen RB; Zheng L; Huang K
Biochim Biophys Acta; 2013 Oct; 1830(10):4860-71. PubMed ID: 23820032
[TBL] [Abstract][Full Text] [Related]
10. Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers.
Bitencourt ALB; Campos RM; Cline EN; Klein WL; Sebollela A
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255488
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins.
Naiki H; Nagai Y
J Biochem; 2009 Dec; 146(6):751-6. PubMed ID: 19643812
[TBL] [Abstract][Full Text] [Related]
12. Structure and intermolecular dynamics of aggregates populated during amyloid fibril formation studied by hydrogen/deuterium exchange.
Carulla N; Zhou M; Giralt E; Robinson CV; Dobson CM
Acc Chem Res; 2010 Aug; 43(8):1072-9. PubMed ID: 20557067
[TBL] [Abstract][Full Text] [Related]
13. Nanobodies: natural single-domain antibodies.
Muyldermans S
Annu Rev Biochem; 2013; 82():775-97. PubMed ID: 23495938
[TBL] [Abstract][Full Text] [Related]
14. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
Meredith SC
Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
[TBL] [Abstract][Full Text] [Related]
15. Shape matters: the complex relationship between aggregation and toxicity in protein-misfolding diseases.
Ries HM; Nussbaum-Krammer C
Essays Biochem; 2016 Oct; 60(2):181-190. PubMed ID: 27744334
[TBL] [Abstract][Full Text] [Related]
16. Review: membrane-associated misfolded protein propagation in natural transmissible spongiform encephalopathies (TSEs), synthetic prion diseases and Alzheimer's disease.
Jeffrey M
Neuropathol Appl Neurobiol; 2013 Apr; 39(3):196-216. PubMed ID: 23171056
[TBL] [Abstract][Full Text] [Related]
17. Conformational diseases: looking into the eyes.
Surguchev A; Surguchov A
Brain Res Bull; 2010 Jan; 81(1):12-24. PubMed ID: 19808079
[TBL] [Abstract][Full Text] [Related]
18. Exploiting Nanobodies' Singular Traits.
Ingram JR; Schmidt FI; Ploegh HL
Annu Rev Immunol; 2018 Apr; 36():695-715. PubMed ID: 29490163
[TBL] [Abstract][Full Text] [Related]
19. Nanobodies®: new ammunition to battle viruses.
Vanlandschoot P; Stortelers C; Beirnaert E; Ibañez LI; Schepens B; Depla E; Saelens X
Antiviral Res; 2011 Dec; 92(3):389-407. PubMed ID: 21939690
[TBL] [Abstract][Full Text] [Related]
20. Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade.
Chiti F; Dobson CM
Annu Rev Biochem; 2017 Jun; 86():27-68. PubMed ID: 28498720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
